HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy.

Abstract
Spinobulbar muscular atrophy (SBMA) is an X-linked neuromuscular disease caused by polyglutamine (polyQ) expansion in the androgen receptor (AR) gene. SBMA belongs to the family of polyQ diseases, which are fatal neurodegenerative disorders mainly caused by protein-mediated toxic gain-of-function mechanisms and characterized by deposition of misfolded proteins in the form of aggregates. The neurotoxicity of the polyQ proteins can be modified by phosphorylation at specific sites, thereby providing the rationale for the development of disease-specific treatments. We sought to identify signaling pathways that modulate polyQ-AR phosphorylation for therapy development. We report that cyclin-dependent kinase 2 (CDK2) phosphorylates polyQ-AR specifically at Ser96 Phosphorylation of polyQ-AR by CDK2 increased protein stabilization and toxicity and is negatively regulated by the adenylyl cyclase (AC)/protein kinase A (PKA) signaling pathway. To translate these findings into therapy, we developed an analog of pituitary adenylyl cyclase activating polypeptide (PACAP), a potent activator of the AC/PKA pathway. Chronic intranasal administration of the PACAP analog to knock-in SBMA mice reduced Ser96 phosphorylation, promoted polyQ-AR degradation, and ameliorated disease outcome. These results provide proof of principle that noninvasive therapy based on the use of PACAP analogs is a therapeutic option for SBMA.
AuthorsMaria Josè Polanco, Sara Parodi, Diana Piol, Conor Stack, Mathilde Chivet, Andrea Contestabile, Helen C Miranda, Patricia M-J Lievens, Stefano Espinoza, Tobias Jochum, Anna Rocchi, Christopher Grunseich, Raul R Gainetdinov, Andrew C B Cato, Andrew P Lieberman, Albert R La Spada, Fabio Sambataro, Kenneth H Fischbeck, Illana Gozes, Maria Pennuto
JournalScience translational medicine (Sci Transl Med) Vol. 8 Issue 370 Pg. 370ra181 (12 21 2016) ISSN: 1946-6242 [Electronic] United States
PMID28003546 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016, American Association for the Advancement of Science.
Chemical References
  • Ligands
  • Peptides
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Androgen
  • Glutamine
  • polyglutamine
  • Cyclic AMP-Dependent Protein Kinases
  • CDK2 protein, human
  • Cdk2 protein, mouse
  • Cyclin-Dependent Kinase 2
Topics
  • Animals
  • Cell Proliferation
  • Cyclic AMP-Dependent Protein Kinases (metabolism)
  • Cyclin-Dependent Kinase 2 (metabolism)
  • Glutamine (metabolism)
  • HEK293 Cells
  • Humans
  • Ligands
  • Membrane Potential, Mitochondrial
  • Mice
  • Mice, Transgenic
  • Muscular Disorders, Atrophic (metabolism)
  • PC12 Cells
  • Peptides (chemistry)
  • Phosphorylation
  • Pituitary Adenylate Cyclase-Activating Polypeptide (pharmacology)
  • Protein Denaturation
  • Protein Folding
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Androgen (metabolism)
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: